CN102021149A - 基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用 - Google Patents
基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用 Download PDFInfo
- Publication number
- CN102021149A CN102021149A CN 201010249755 CN201010249755A CN102021149A CN 102021149 A CN102021149 A CN 102021149A CN 201010249755 CN201010249755 CN 201010249755 CN 201010249755 A CN201010249755 A CN 201010249755A CN 102021149 A CN102021149 A CN 102021149A
- Authority
- CN
- China
- Prior art keywords
- gene
- virus
- respiratory syncytial
- cell
- syncytial virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title claims abstract description 77
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 18
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 16
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 14
- 230000006735 deficit Effects 0.000 title abstract 4
- 210000004027 cell Anatomy 0.000 claims abstract description 53
- 241000700605 Viruses Species 0.000 claims abstract description 29
- 210000003501 vero cell Anatomy 0.000 claims abstract description 9
- 239000002299 complementary DNA Substances 0.000 claims abstract description 6
- 101150062031 L gene Proteins 0.000 claims abstract description 5
- 101150084044 P gene Proteins 0.000 claims abstract description 5
- 230000002950 deficient Effects 0.000 claims description 14
- 238000013326 plasmid cotransfection Methods 0.000 claims description 5
- 206010052428 Wound Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 201000005296 lung carcinoma Diseases 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 239000013612 plasmid Substances 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 description 23
- 230000006907 apoptotic process Effects 0.000 description 16
- 101150033828 NS1 gene Proteins 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 10
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 230000008965 mitochondrial swelling Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101150095629 NS2 gene Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010249755 CN102021149B (zh) | 2010-07-27 | 2010-07-27 | 基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010249755 CN102021149B (zh) | 2010-07-27 | 2010-07-27 | 基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102021149A true CN102021149A (zh) | 2011-04-20 |
CN102021149B CN102021149B (zh) | 2013-04-24 |
Family
ID=43862933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010249755 Expired - Fee Related CN102021149B (zh) | 2010-07-27 | 2010-07-27 | 基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102021149B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103330723A (zh) * | 2013-01-14 | 2013-10-02 | 艾克星(武汉)生物医药科技有限公司 | 基因工程呼吸道合胞病毒(△ns1 rsv)在治疗癌症药物中的用途 |
JP7034521B1 (ja) * | 2021-12-08 | 2022-03-14 | 伸一 原田 | がんワクチン及びがんワクチンの製造方法 |
CN114990079A (zh) * | 2022-04-29 | 2022-09-02 | 广州医科大学附属第一医院(广州呼吸中心) | 治疗性缺陷干扰颗粒及其在制备用于防治rsv病毒感染的产品中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1224462A (zh) * | 1996-07-15 | 1999-07-28 | 美国政府健康及人类服务部 | 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法 |
CN1312725A (zh) * | 1998-06-12 | 2001-09-12 | 纽约城市大学辛乃山医科学校 | 用作疫苗和药剂的具有被改变的干扰素拮抗剂活性的减毒负链病毒 |
CN1426462A (zh) * | 2000-04-26 | 2003-06-25 | 惠氏 | 抗干扰素(ifn)反应的肺炎病毒非结构蛋白 |
WO2009039178A1 (en) * | 2007-09-20 | 2009-03-26 | Pontificia Universidad Catolica De Chile | Immunogenic formulation |
CN102021148A (zh) * | 2010-07-27 | 2011-04-20 | 张卫东 | 一种基因ns1缺陷型呼吸道合胞病毒及其应用 |
-
2010
- 2010-07-27 CN CN 201010249755 patent/CN102021149B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1224462A (zh) * | 1996-07-15 | 1999-07-28 | 美国政府健康及人类服务部 | 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法 |
CN1312725A (zh) * | 1998-06-12 | 2001-09-12 | 纽约城市大学辛乃山医科学校 | 用作疫苗和药剂的具有被改变的干扰素拮抗剂活性的减毒负链病毒 |
CN1426462A (zh) * | 2000-04-26 | 2003-06-25 | 惠氏 | 抗干扰素(ifn)反应的肺炎病毒非结构蛋白 |
WO2009039178A1 (en) * | 2007-09-20 | 2009-03-26 | Pontificia Universidad Catolica De Chile | Immunogenic formulation |
CN102021148A (zh) * | 2010-07-27 | 2011-04-20 | 张卫东 | 一种基因ns1缺陷型呼吸道合胞病毒及其应用 |
Non-Patent Citations (1)
Title |
---|
《重庆医科大学博士学位论文》 20021231 赵长安 脱氧核酶抗呼吸道合胞病毒效应的体外研究 1-3 , * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103330723A (zh) * | 2013-01-14 | 2013-10-02 | 艾克星(武汉)生物医药科技有限公司 | 基因工程呼吸道合胞病毒(△ns1 rsv)在治疗癌症药物中的用途 |
JP7034521B1 (ja) * | 2021-12-08 | 2022-03-14 | 伸一 原田 | がんワクチン及びがんワクチンの製造方法 |
CN114990079A (zh) * | 2022-04-29 | 2022-09-02 | 广州医科大学附属第一医院(广州呼吸中心) | 治疗性缺陷干扰颗粒及其在制备用于防治rsv病毒感染的产品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102021149B (zh) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Naik et al. | Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways | |
JP6441372B2 (ja) | アルファウイルスの抗腫瘍薬の製造への応用 | |
JP6980762B2 (ja) | 抗腫瘍薬の調製におけるvcp阻害剤及び腫瘍溶解性ウイルスの使用 | |
Cheng et al. | Toll-like receptor 3 inhibits Newcastle disease virus replication through activation of pro-inflammatory cytokines and the type-1 interferon pathway | |
Liu et al. | MicroRNA modification of coxsackievirus B3 decreases its toxicity, while retaining oncolytic potency against lung cancer | |
Qadir et al. | miRNA in hepatocellular carcinoma: pathogenesis and therapeutic approaches | |
Liu et al. | Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses | |
Biswas et al. | Cell-type-specific innate immune response to oncolytic Newcastle disease virus | |
Bin Liu et al. | Virus, oncolytic virus and human prostate cancer | |
CN102021149B (zh) | 基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用 | |
Futami et al. | Efficacy and safety of doubly-regulated vaccinia virus in a mouse xenograft model of multiple myeloma | |
Li et al. | Deficiency of the IRE1α-autophagy axis enhances the antitumor effects of the oncolytic virus M1 | |
Li et al. | Change in the single amino acid site 83 in rabies virus glycoprotein enhances the BBB permeability and reduces viral pathogenicity | |
Geletneky et al. | Improved Killing of Human High‐Grade Glioma Cells by Combining Ionizing Radiation with Oncolytic Parvovirus H‐1 Infection | |
Gillet et al. | Bovine herpesvirus 4 induces apoptosis of human carcinoma cell lines in vitro and in vivo | |
Bastin et al. | Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference | |
CN102021148A (zh) | 一种基因ns1缺陷型呼吸道合胞病毒及其应用 | |
WO2022033469A1 (zh) | 重组溶瘤病毒及其构建方法和用途 | |
US8597637B1 (en) | Breast cancer therapy using an engineered respiratory syncytial virus | |
WO2019174610A1 (zh) | 一种溶瘤病毒、合成dna序列及其应用 | |
CN101596316A (zh) | 表达FoxMlsiRNA的重组腺病毒及其在肿瘤治疗和预防中的应用 | |
CN102250904B (zh) | 一种预防和/或治疗黑色素瘤的药物 | |
Pathak et al. | NDV as an Oncolytic Agent–Study in Cancer Cell Lines | |
Naserpour Farivar et al. | Capsid Modified Bluetongue Virus 16 (BTV16) as a Virulytic Oncotherapy Agent | |
Liu et al. | microRNA Modification of Coxsackievirus B3 Decreases Its Cardiotoxicity, While Retaining Oncolytic Potency Against Lung Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JIANG LIXIAN CAI LIGANG GAO LIWEI Free format text: FORMER OWNER: JIANG LIXIAN GAO LIWEI Effective date: 20130128 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Weidong Inventor after: Jiang Lixian Inventor after: Cai Ligang Inventor after: Gao Liwei Inventor before: Zhang Weidong Inventor before: Jiang Lixian Inventor before: Gao Liwei |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG WEIDONG JIANG LIXIAN GAO LIWEI TO: ZHANG WEIDONG JIANG LIXIAN CAI LIGANG GAO LIWEI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130128 Address after: Tampa, Florida, Miami, USA 20119 Applicant after: Zhang Weidong Applicant after: Jiang Lixian Applicant after: Cai Ligang Applicant after: Gao Liwei Address before: Tampa, Florida, Miami, USA 20119 Applicant before: Zhang Weidong Applicant before: Jiang Lixian Applicant before: Gao Liwei |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130424 Termination date: 20150727 |
|
EXPY | Termination of patent right or utility model |